



NEWSLETTER

DERMATOLOGY.STANFORD.EDU

WINTER 2013-2014

INSIDE THIS ISSUE:

Chairman's Message
1-2

**New Faculty
Members**
3-4

Former Residents
5

New Residents
6

Grand Rounds
6

Clinical Trials
7-8

**Cutaneous Oncology
Program**
9-11

Giving Opportunities
12

Events
13-15

Letter from the Chair

Dear Colleagues

On behalf of the Department of Dermatology, I am pleased to convey our best wishes for a wonderful winter holiday season. It was great to have our community gather in early December at the Annual Department Holiday Party, which took place at Schwab Center at Stanford on December 6. Over 300 faculty, staff, trainees, alumni, family, and friends from the Department's many clinical and research sites came together for a wonderful dinner evening. Please see photos from the event on pages 13-14 of the newsletter. Just as this past holiday gathering represents an important yearly "Reunion" of our community here at home, our Department Reunion at this year's American Academy of Dermatology Meeting in Denver on the evening of March 23rd from 6PM-8PM in the Regency Mineral FG room at the Denver Hyatt Regency represents a chance to connect with the more widely dispersed alumni and friends of Stanford Dermatology. Please mark your calendars and join us for a chance to renew ties with alumni and current faculty at the AAD.



Since our spring newsletter, there have been positive new developments in Stanford Dermatology, including the addition of a number of new faculty (please see pages 3-4). Dr. Jennifer Chen, an outstanding young medical Dermatologist who completed her M.D. at Johns Hopkins and did research work at Stanford, joined the Department after completing her residency at UC Irvine in August. Dr. Chen has a strong interest in complex medical Dermatology. She will attend in our inpatient consult service as well as in our newly revitalized patch testing clinic. Dr. Lisa Zaba, a superb physician-scientist who completed her M.D., Ph.D. studies at Cornell and Rockefeller, joined the Department after completing her residency here at Stanford. Dr. Zaba is pursuing clinical interests in immune mediated skin disease. Dr. Aruna Venkatesen, another outstanding medical Dermatologist, completed her M.D. at UCSF and her Dermatology residency training here at Stanford before joining our faculty this year based at the Santa Clara Valley Medical Center. Dr. Venkatesen has a strong interest in medical Dermatology, resident education and vulvar dermatoses. Dr. Kevin Wang, a superb physician-scientist who completed his Ph.D. at Harvard and his M.D. at UCSF, joined the Department after completing a postdoctoral fellowship here in the laboratory of Howard Chang. Dr. Wang's laboratory is studying epigenetic mechanisms in wound regeneration and skin disease. The addition of these new faculty contribute to what has

become the largest period of growth for the Department in its history.

In other progress, the Department's specialty care and clinical research efforts continue to multiply, including in the area of both fundamental scientific advances as well as translational clinical trials (please see pages 7-11). The Pediatric Dermatology specialty programs and clinical trials, led by Dr. Alfred Lane, Dr. Latanya Benjamin and Program Director Dr. Joyce Teng, continue to grow, including for lymphovascular malformations and genodermatoses. The Cutaneous Oncology Program continues to expand its specialty clinical and research programs. These include the Pigmented Lesion and Melanoma Program led by Dr. Susan Swetter, the Cutaneous Lymphoma Program, led by Dr. Youn Kim, and the Supportive Dermato-Oncology Program led by Dr. Bernice Kwong. The Dermatology Surgery Program, under the capable leadership of Dr. Sumaira Aasi, continues to conduct collaborative research and cutting edge skin cancer surgical care. The Adverse Drug Reaction Clinic, led by Dr. Kavita Sarin, has now launched and is bringing the latest in personalized genomic medicine analysis and care to its patients. The Autoimmune Clinic, led by Dr. David Fiorentino, the Genital Dermatology Clinic, led by Dr. Joanna Badger, and the Blistering Clinic, led by Dr. Peter Marinkovich, continue to provide leading edge clinical care and research programs. Finally, the Contact Dermatitis/Patch Test Clinic is being revitalized this winter under the leadership of Dr. Jennifer Chen. All these specialty care and clinical research efforts continue to help serve our community and to train our Residents and students in a setting that advances the state of knowledge in the field.

In additional positive developments, the Fourth Annual Faculty Retreat in our Department's new Multi-Task Force working format was held on September 20, 2013 at the Stanford Faculty Club. Faculty came together to work on issues important to the Department's continued success, with a special focus for this year's Retreat on enhancing our Education and Patient Care missions. The Retreat itself was the culmination of months of advance work by Task Forces led by faculty members active in each of those areas, including Dr. David Fiorentino and Dr. Justin Ko. These Task Forces helped chart the path forward for this year's plan Department growth and improvement, with a number of additional initiatives now either underway or already completed. Plans are in place for next year's Retreat in September, 2014.

Looking to the future, the mission of the Department will remain focused, as it has been for past decades, on leadership in discovery, in patient care and in training leaders of our specialty in an environment that fosters creativity, excellence and synergy. The support of our entire community of faculty, alumni, patients, and friends will be instrumental in providing the creativity and resources needed in this effort to support trainees, young faculty, patient care advances and innovative research. We invite you to continue your valued contributions to the Department and to our entire Dermatology community.

I welcome your support and suggestions to enhance these endeavors and thank you for your efforts as part of the Stanford Dermatology community.

With best wishes for a happy holiday season and New Year,

Paul Khavari, MD, PhD
Carl J. Herzog Professor and Chairperson




New Faculty members



Jennifer Chen, M.D.


Jennifer Chen, M.D. joined the Department of Dermatology at Stanford University as a new faculty member in August 2013. She received her B.A. with Honors in Molecular and Cell Biology, and had received the UC Berkeley Alumni Association Emerging Leader Scholarship, Yuan T. Lee Scholarship, and the Golden Key Honor Society award. Dr. Chen had earned her Medical Doctor degree from Johns Hopkins University School of Medicine, where she was recruited to Alpha Omega Alpha honor society. Prior to residency, she had completed a one year Howard Hughes fellowship in the Khavari Lab conducting research on human genetic skin disease, and a one-year internship at John Hopkins Bayview Hospital. She has a strong passion in the education of medical students, colleagues, and residents, particularly fostering their abilities to recognize dermatologic emergencies and distinguish between similar-appearing entities. She is interested in complex medical dermatology with particular interests in inpatient dermatology, contact dermatitis, and granulomatous disorders.

Kavita Sarin, M.D., Ph.D., began working as a Clinical Assistant Professor of Dermatology as of February 2013. Her background consists of a Bachelor of Science in Computer Science, where she achieved first place in her Synaptics thesis, followed by completing a Ph.D. in Genetics in 2006, where she was granted the American Association Cancer Research (AACR) Scholar in Training award, and the NIH Medical Scientist Training Grant. In 2008, Dr. Sarin received her M.D. at Stanford University School of Medicine. She is a graduate of the Stanford Dermatology Residency Program June 2012 class. Along with her residency training, Dr. Sarin had spent her time as a concurrent postdoctoral fellow conducting basic science research in the Khavari Lab, in which she focused on identifying genetic variants in childhood skin tumors using exome sequencing. She is the lead in our new personalized dermatologic genomic medicine program, where she is able to create new relationships with the medical genetics physicians here at Stanford.




Kavita Sarin, M.D., Ph.D.

Lisa Zaba, M.D., Ph.D. began working as a Clinical Instructor of Dermatology on July 1, 2013. Dr. Zaba earned her B.S. in Biology, *Magnum cum laude*, from Stanford University, then accepted as a M.D.-Ph.D. student at the Tri-Institutional Program at Cornell and Rockefeller University, where she published 20 peer-reviewed papers in high impact journals such as *Journal of Clinical Investigation* and *Journal of Experimental Medicine* in the area of psoriasis immunology. Through her numerous publications and presentations at national and international meetings, Dr. Zaba became known as an expert in human skin immunology. She completed her Dermatology residency from our Stanford program in the Summer of June 2013. She is a budding young physician-scientist involved in the study of gene regulation of autoimmune disease.



Lisa Zaba, M.D., Ph.D.



Kevin Wang, M.D., Ph.D. was appointed by the Department of Dermatology as Assistant Professor in the University Tenure Line on October 1, 2013. Dr. Wang was previously an Instructor, and a postdoc at Stanford, in the laboratory of Howard Chang, M.D., Ph.D. Dr. Wang earned his Master of Philosophy in Biological Sciences from the University of Cambridge in the United Kingdom, followed by his Doctor of Philosophy in Neurobiology from Harvard Medical School, and Doctor of Medicine from UCSF. Dr. Wang's research interests are focused on molecular mechanisms of epigenetic regulation of gene expression, and his overall investigative program will help in understanding clinically relevant issues in dermatology such as wound regeneration and site-specific disease manifestations.

Kevin Wang, M.D., Ph.D.

Aruna Venkatesan, M.D., is a Clinical Assistant Professor who serves as Associate Chief of Dermatology at Santa Clara Valley Medical Center. She earned two Bachelors of Science degrees in Biomedical Engineering, and in Biological Anthropology and Anatomy as a *summa cum laude* in 2004 at Duke University. She then completed a year in advanced training in clinical research methodology at UCSF, in the Department of Epidemiology and Biostatistics, followed by the completion of her medical degree in 2009. She is a graduate of our June 2013 Dermatology residency program. Dr. Venkatesan's professional interests are in general outpatient dermatology, inpatient consultative dermatology, resident education, and with a significant subspecialty expertise in female genital dermatology.



Aruna Venkatesan, M.D.

2013 Residency Graduates



Erik Cabral, M.D. - Stanford University, B.A.; Stanford University School of Medicine, M.D. Santa Clara County Valley Medical Center, Internship. Currently: Fellow in Mohs micrographic surgery program with Dr. Richard Bennett in Los Angeles, CA.

Tyler Hollmig, M.D. - Duke University, B.A.; University of Texas Southwestern Medical School, M.D. Texas Health Resources Presbyterian Hospital, Internship. Currently: Mohs micrographic surgery Fellow at Medical University of South Carolina.



Aruna Venkatesan, M.D. - Duke University, B.S.E.; University of California, San Francisco, M.D.; Kaiser Permanente San Francisco, Internal Medicine, Internship. Currently: A Clinical Assistant Professor at Santa Clara Valley Medical Center.

Ashley Wysong, M.D. - University of Missouri, B.S.; Stanford University, M.S.; Duke University, M.D.; Duke University Medical Center, Internship. Currently: Procedural Dermatology Fellow at Scripps Clinic in La Jolla, CA.



Lisa Zaba, M.D., Ph.D. - Stanford University, B.S.; Rockefeller University, Ph.D.; Cornell University, M.D.; Memorial Sloan-Kettering, Internship. Currently: A Clinical Instructor at Stanford Hospitals and Clinics.



Stanford Dermatology welcomed the following new residents in July 2013

Meghan Dickman, M.D.- University of California, San Francisco
Milene Crispin, M.D.- Cornell University Joan and Sanford Weil Medical College
Anna Rogers, M.D.- Emory University School of Medicine
Leon Hsu, M.D.- University of California, Davis
Laura Bernet, M.D.- University of California, Los Angeles
Laurel Geraghty, M.D.- New York University

Grand Rounds Schedule

Every Thursday from 7:30AM - 9:00 AM unless noted otherwise:

January 30, 2014 - SMOC, Redwood City
February 6, 2014 - Cancelled
February 13, 2014 - SMOC, Redwood City
February 20, 2014 - Cancelled
February 27, 2014 - SMOC Redwood City
March 6, 2014 - SCVMC, San Jose
March 13, 2014 - SMOC, Redwood City

Clinical Trials



Pediatric Dermatology

Sildenafil for Treatment of Lymphatic Malformations:

Planned multi-site placebo-controlled study on sildenafil for the treatment of lymphatic malformations (LMs) is projected to receive funding from FDA's Orphan Products Grant Program and begin enrolling in the first half of 2014. Children 6 months to 10 years old with one or more LMs that are at least 3cm in diameter by MRI measurement will be enrolled. Subjects have a 2:1 chance of receiving 20 weeks of sildenafil over placebo, and those who receive 20 weeks of placebo will have the option to take sildenafil for an

additional 20 weeks. At screening, the subjects will undergo a MRI, eye exam, hearing exam, blood tests, and evaluation by study investigator, and after 20 weeks of sildenafil will have another MRI. There are a total of 6 visits, with more if the subject opts for sildenafil after placebo.

PI: Alfred Lane, MD.

For more information, please contact Andrea Tichy at atichy@stanford.edu or 650-724-1982

Biomarker Levels Before and After Sildenafil for Lymphatic Malformations:

Subjects enrolled in Dr. Lane's sildenafil study for lymphatic malformations (LMs) will have the option to also enroll in a study on biomarkers that are known or suspected to be related to LMs. Biomarker levels will be assessed from blood taken at the sildenafil study's Screening visit and Week 20 visit. Biomarkers may give investigators a better idea of the characteristics of LMs that respond well to sildenafil, as well as increase overall knowledge of LM characteristics, essential to developing more treatment options for this rare condition. PI: Alfred Lane, MD, Co-PI: Joyce Teng, MD/PhD.

Pachyonychia Congenita & Lamellar Ichthyosis Trials

Topical Rapamycin for Plantar Keratoderma in Adults with Pachyonychia Congenita:

This study hopes to improve the clinical severity of plantar keratoderma, including pain. Enrollment will begin by Jan 2014.

PI: Joyce Teng, MDPhD.

Efficacy, Safety, and Pharmacokinetics of 2 Concentrations and 2 Dosage Regimens of CD5789 in Subjects with Lamellar Ichthyosis:


Stanford is conducting a new study that uses a topical drug for patients of a retinoid that is formulated as a cream (CD5789 Cream). This research study is expected to take approximately 14 weeks, including a screening period up to 4 weeks, a 6-week treatment period and a 4-week follow-up period. Enrollment will begin early 2014. PI: Joyce Teng, MD/PhD.

For more information on these clinical trials, please contact Rasidat Adeduntan at radeduntan@stanford.edu

Clinical Trials

Cutaneous Lymphoma Program

Currently enrolling clinical trials:



Youn Kim, M.D.

- Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients with Mycosis Fungoides and Sezary Syndrome with Variable CD30 Expression Level
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1B Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP-141, a Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients with Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
- A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN 35) Versus Physician's choice (Methotrexate or Bexarotene) in Patients with CD30-Positive Cutaneous T-Cell Lymphoma
- Mogamulizumab (KW-0761), a bioengineered, humanized monoclonal antibody against CCR4, a target selectively expressed on tumor cells; phase III study in mycosis fungoides and Sezary syndrome, stages IB-IV
- A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-thymocyte Globulin (ATG) In Patients with Cutaneous T Cell Lymphoma

For all questions concerning these clinical trials, and referral of potential patients, please contact Dr. Youn Kim at younkim@stanford.edu or 650-521-3545

Please welcome our new members to the Cutaneous Lymphoma Program

New Patient Coordinator: Silvia Pena-Sandaval
spsandoval@stanfordmed.org • 650-498-6000

Nurse Coordinator: Kristen Markel
kmarkel@stanfordmed.org • 650-498-6000

Fellow: Sima Rozati
srozati@stanford.edu • 650-725-3292

Cutaneous Oncology

Pigmented Lesion and Melanoma Program Highlights

Susan Swetter, M.D., Director

Stanford Pigmented Lesion and Melanoma Program (PLMP):

Stanford PLMP Director, Dr. Susan Swetter, Professor of Dermatology, recently collaborated with epidemiologists at the Cancer Prevention Institute of California (CPIC) to demonstrate survival differences between adolescent and young adult men and women with cutaneous melanoma (*published in JAMA Dermatology*). This novel research presents further evidence in support of a biologic mechanism behind the sex disparity in melanoma survival, and the contributing factors being explored in conjunction with Stanford Dermatology basic scientists.



Susan Swetter, M.D.

Melanoma Surgery, Stanford Cancer Center:

Stanford Clinical Associate Professor Sumaira Aasi, MD, Director of Mohs and Dermatologic Surgery at the Stanford Medicine Outpatient Center, continues to expand cutaneous surgical treatment of melanoma and nonmelanoma skin cancers in the Dermatology Department. The Skin Cancer Program uses SLNB to detect microscopic spread of melanoma and Merkel cell carcinoma in regional lymph nodes with novel imaging modalities and research to improve accuracy. Significant advances in localizing sentinel lymph nodes have occurred over the years, and Stanford melanoma surgeons John Sunwoo, MD and Ralph Greco, MD work closely with the Stanford Division of Nuclear Medicine and Molecular Imaging during the preoperative assessment and lymphatic mapping. Dr. Greco is currently evaluating the role of Spy imaging in identifying sentinel lymph nodes in melanoma patients.

Melanoma Translational Research Highlights:

Studies of the innate immune response to melanoma cancer stem cells and what regulates this response are being conducted in the laboratory of melanoma head and neck surgeon Dr. John Sunwoo. He collaborates with tumor immunologist Holbrook Kohrt, MD, PhD, Assistant Professor of Medicine, Hematology and Oncology, who is the principal investigator of a novel single institution phase I/II study of intratumoral injection of ipilimumab in combination with local radiation in melanoma, non-Hodgkin lymphoma and colorectal carcinoma (VAR0090). In melanoma models, this combination of localized therapy has resulted in systemic tumor shrinkage. Ongoing assessment of the synergistic effects of radiation therapy and systemic ipilimumab is in progress in a early phase trials under the direction of Dr. Susan Knox, Professor of Radiation Oncology at Stanford. Identification of genetic alterations and pathways of melanoma development are also in progress in the laboratory of Dr. Paul Khavari, Professor and Chair of Dermatology, and will provide powerful therapeutic options for patients diagnosed with all stages of melanoma.

Cutaneous Oncology

Melanoma Clinical-Epidemiological Research and Program Development:

In January 2013, Robert Haile, DrPH, joined the faculty at Stanford as Professor in the Department of Medicine and Associate Director of Population Sciences at the Stanford Cancer Institute. Major initiatives started by Dr. Haile include enhancing the clinical translational impact of genomics-based research, enhancing biological and behavioral research that will result in earlier detection of cancer, expanding survivorship research, and expanding research in multiple racial/ethnic groups, all of which align with the goals of the Stanford Skin Cancer Program.

Epidemiologic research:

Jean Tang, MD, PhD, Associate Professor of Dermatology, Marcia Stefanick, PhD, Professor of Medicine at the Stanford Prevention Research Center, and Dr. Swetter utilized the Women's Health Initiative Observational Study data to demonstrate that postmenopausal women ages 50 to 79 years who used aspirin had a 21% lower risk of developing melanoma. The risk was even lower (30%) for women who used aspirin for at least five years. While this study is not a randomized clinical trial, the observed association is significant and warrants further investigation. Stanford investigators recently initiated the first trial of high dose vitamin D (4,000 IU) on precursor melanoma cells in women.

New Program Development in Supportive Dermato-Oncology and Cutaneous Malignancies Dermatology and Surgical Programs:

In the fall of 2012, Dr. Bernice Kwong, Clinical Assistant Professor in Dermatology, initiated the first Supportive Dermato-Oncology Program within the Stanford Cancer Center (SCC). This one-of-a kind program allows for direct dermatology evaluation of patients undergoing cancer therapy to address cutaneous complications related to cancer diagnosis and skin side effects of cancer treatment that may severely impact a patient's day-to-day activities and/or prevent ongoing therapeutic intervention. The reception of Dr. Kwong's efforts in the SCC by both patients and staff has been remarkable, and treating debilitating skin conditions in cancer patients has allowed them to continue treatment in many cases.

In 2012, former Clinical Assistant Professor of Dermatology, Dr. Michael Krathen, introduced a novel Post-Transplant / High Risk Skin Cancer Clinic in Stanford Dermatology, focused on patients who are at a high risk of developing skin cancer (especially squamous cell carcinoma) due to various causes, including immune suppression therapy following a solid organ transplant. Leadership of this clinic has transitioned to Clinical Instructor in Dermatology Carolyn Lee, MD, PhD, and will involve ongoing collaboration with medical and surgical oncology colleagues for treatment and prevention approaches.

Stanford Merkel Cell Program:

Merkel cell carcinoma, also called neuroendocrine cancer of the skin, is a rare skin cancer, although incidence is on the rise in the US. Merkel cell carcinoma (MCC) is usually found on the sun-exposed areas of the head, neck, arms, and legs of older, fair-complexioned individuals but can occur in people of other races and ages. The Stanford Merkel Cell Program offers a multidisciplinary approach to the treatment of MCC, utilizing the expertise of Stanford surgeons for wide local excision and SLNB staging. Under the direction of Dr. Kohrt, the Multidisciplinary MCC Program at Stanford is pursuing research regarding newer immunotherapies to treat advanced disease.

Cutaneous Oncology

SUNSPORT:

Stanford University Network for Sun Protection, Outreach, Research, and Teamwork is a unique initiative that stems from collaboration among Stanford Dermatology, Stanford Athletics (including Sports Medicine and Athletic Trainers), Stanford Cancer Institute, and Stanford Hospital and Clinics to create an integrated research, education and intervention program dedicated to providing skin cancer risk awareness and sun-protection education to student athletes, fans and supporters, and the Stanford community at large. Plans to expand the educational messages to younger, school-age athletes and outdoor enthusiasts are in progress.

Pigmented Lesion and Melanoma Program Clinical Trials

- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alfa-2b for Resected High-risk Melanoma Stage IIIB, IIIC, or IV (M1a, M1b) (ECOG1609)
- A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas (ECOG2607)
- A Pilot Study of Ipilimumab in Subjects with Stage IV Melanoma Receiving Palliative Radiation Therapy (MEL0005)
- A Phase III, Randomized, Double-blind, Placebo-controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence (MEL0006)
- A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib versus Vemurafenib plus GDC-0973 in Previously Untreated BRAFV600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (MEL0007)
- The NEMO Trial (NRAS Melanoma and MEK Inhibitor): A Randomized Phase III, Open Label, Multicenter, Two-Arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients with Advanced Unresectable or Metastatic NRAS Mutation-Positive Melanoma (MEL0008)
- A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination with Local Radiation in Melanoma, Non-Hodgkin Lymphoma and Colorectal Carcinoma (VAR0090)
- A Pilot Study of Vitamin D supplements for reduction of melanoma-associated genes in women (SKIN0010)
- Testing the Efficacy of Indocyanine Green Imaging (ICG-SPY) in the Identification of Sentinel Lymph Nodes in Patients with Malignant Melanoma (MEL0010)

Nurse Coordinator: Laura Morris, RN, lmorris@stanfordmed.org
New Patient Coordinator: Silvia Pena-Sandoval, spsandoval@stanfordmed.org

Cutaneous Oncology

Basal Cell Carcinoma Clinical Trials

- A Phase 2 Randomized Double Blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma (SKIN0008)
- A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated with Non-LDE225 Smoothened Inhibitor(s) (SKIN0009)
- Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers (SKIN0010)
- A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCC) (SKIN0012)
- A Pilot Study to Investigate the Off Label Use of Arsenic Trioxide for Basal Cell Carcinoma (BCC) (SKIN0015)
- A Phase II Study of Capecitabine in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Skin (SKIN0016)
- A Randomized, Double-Blinded, Regimen-Controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients with Multiple Basal Cell Carcinomas (SKIN0017) (SOON TO OPEN)

Moving Forward: Ways of giving

The Stanford Department of Dermatology is among the country's leading dermatology programs, as evidenced by our nationally recognized teaching and research programs. To reach a new level of expertise and service; however, will require the support of those who share our passion to revealing the underlying causes of the most devastating skin diseases, and then translating that knowledge into better care for our patients everywhere. At the heart of any great institution are the people whose vision and talent define it. In the Stanford Department of Dermatology, our ability to attract and retain leading clinicians and most promising residents is limited only by our resources.

Here are some of the ways you can make your tax deductible gift to the Department of Dermatology and make a difference: outright gifts, pledges, planned giving, gifts of securities, bequests, tribute gifts, and matching gifts. Also consider endowed funding as well as seed support to underwrite a Professorship or Faculty Scholar Fund, or perhaps a Postdoctoral Fellowship. There are many critical areas of opportunity where your contribution counts.

For more information please contact Cathy Hutton at chutton1@stanford.edu or Phil Yamahiro at yamahiro@stanford.edu

If interested in donating, please send checks to:

**PAUL A. KHAVARI, MD, PHD, CHAIR, 450 BROADWAY STREET, REDWOOD CITY, CA 94063
C/O PHIL YAMAHIRO, DFA**

Dermatology Holiday 2013 Party

On Friday, December 6, 2013, the Department of Dermatology held its Annual Holiday Party at the Schwab Residential Center's Vidalakis Ballroom. The event brought together many faculty, staff, and family members from our Stanford, Redwood City, VA, Lucile Packard, and Santa Clara Medical centers. Thanks to Bllew Photography and to our Holiday Faerie balloon artist for their wonderful services to our celebration. An enjoyable time was had by all and we look forward to celebrating the holidays again next year!






Upcoming Events

Stanford Dermatology AAD Reunion - March 23, 2014

The Department of Dermatology will be hosting a reunion at the 72nd AAD Annual Meeting in Denver, Colorado on March 23, 2014. All former and current faculty, residents, and alumni of the Stanford Dermatology Community are welcome to join.



Please RSVP to Vanessa Aczon at vaczon@stanford.edu

Society for Investigative Dermatology - May 7, 2014 - May 10, 2014

The Society of Investigative Dermatology (SID) will be holding its 2014 SID Annual Meeting at the Albuquerque Convention Center (ACC) in Downtown Albuquerque, New Mexico.

Registration now open: www.sid.org

Important Dates

January 21, 2014

Resident Interviews

Stanford, CA

March 21 - 25, 2014

AAD Annual Meeting

Denver, CO

May 7 - 10, 2014

SID Annual Meeting

Albuquerque, NM



Stanford Dermatology Faculty 2014